US approves breakthrough HIV jab – but aid cuts mean it may not get to millions in need - FDA approval paves the way for the jab to roll out across the world. But with funding being slashed, will it get to the people who need it?

A twice-yearly injectable drug for the prevention of HIV infection has been approved by the United States’ Food and Drug Administration. With better compliance expected — instead of daily pills on a shot every two months that people have to take at the moment — it is one of the most anticipated developments in the field of HIV prevention.

Learn more about lenacapavir, the most effective HIV treatment and prevention drug, and how its cost could cause a setback.